Best Tirzepatide Vendors for Research (April 2026)

Of 1,776 tirzepatide samples sent to independent labs, 22% failed quality standards and 12% diverged from the labeled dose by more than 20%. A vial can test at 99% pure and still contain half the mg printed on the label.

The best tirzepatide vendors are the ones who prove both numbers, not just the flattering one. Purity and quantity accuracy are two different measurements, and the peptide industry talks about one while hiding the other. Regulatory pressure has thinned the field fast. FDA removed tirzepatide from the shortage list in December 2024. The ITC issued a General Exclusion Order on infringing imports in January 2025. Peptide Sciences, once a $7.4M-per-month operation, shut down on March 6, 2026.

Every vendor below is still shipping as of April 2026 with independent third-party batch data on file. They are ordered by confidence in that data, not by affiliate rates. Grades weight quantity accuracy as heavily as HPLC purity, because the second metric is where most of the industry quietly fails. Sample depth matters too: a Grade A built on 15 independent batches is a different claim than a Grade A built on 4.

Two cautionary entries sit at the end because transparency cuts both ways. A vendor shipping 47 tested batches with a +43% overfill problem tells you more than a vendor shipping 4 clean ones.

1. Polaris Peptides: Grade A, Deepest Sample History

Polaris Peptides has 15 independently tested tirzepatide batches on record, average score 8.8, and none below 99.3% purity. That sample depth is roughly double the next-best vendor on the list, and sample depth matters more than any single high score.

A Grade A built on 15 batches is a different claim than a Grade A built on 4. Variance has had room to show up and mostly has not. Batch POL-T10-8 posted a perfect 10.0 in one independent pull, and 14 of the 15 tests scored above 7.5 with most above 8.5.

Pricing is competitive without being a red flag: $45 for 5mg, $89 for 10mg, $240 for 30mg, and $330 for 50mg. That is in the same band as Skye and below Peptide Sciences' final published pricing before shutdown. Polaris uses a transparent batch ID format, POL-T[size]-[batch#], which means the number on the vial cross-references directly to the COA for that specific lot.

What to watch. One August 2025 test scored 6.5 on a 40mg vial with +9.4% quantity variance and no batch ID printed on the container. A single outlier on a 15-sample history is not a Grade A threat, but an unlabeled vial is a sourcing red flag by itself. The “lowest variance on the board” claim holds on average and breaks on that one lot. Polaris also does not publish COAs on product pages. You request them from customer support, and the shop itself requires membership and login before you can browse. There is no public endotoxin panel either, which is the component Skye makes a differentiator.

For a researcher building a multi-month protocol, the missing endotoxin data is a gap worth closing with an independent validation pull before the work starts.

Best for: researchers who want the deepest sample history on the board and will request COAs and reject unlabeled vials on arrival.

2. Skye Peptides: Grade A, Only Vendor Publishing a Full COA Panel

Skye Peptides is the only vendor in our database that publishes a full four-panel COA for public download before purchase: HPLC purity, endotoxin at 0.25 EU/mg on batch TZ25-30-004, sterility, and heavy metals. Every panel is run through Janoshik, and each COA carries a QR code and unique verification key that resolves against the lab's own records at public.janoshik.com.

Endotoxin data is the COA component most commonly hidden. The USP limit for injectable research compounds is 5 EU/mg. Skye is reporting 0.25, which is twenty times inside the limit, and they are reporting it in public where you can read it before you spend a dollar.

Grade A, score 7.9 across 11 samples. The 7.9 sits below Polaris (8.8) and Atomik (8.4), and that is the honest tradeoff. Skye is selling a transparency package, not a highest-score vanity metric. On risk-adjusted terms, a Grade A with every panel visible beats a higher score with partial disclosure. You get to match lot number to published document today, which is the part most vendors quietly skip.

Quantity data is conservative in a different direction than most of this list. Batch TZ24-10-009 (10mg) measured 11.3 to 11.8mg actual, a +3% to +7% overfill that stays inside the acceptable band. Skye lists the compound as “GLP-1 T” in 10mg, 30mg, 40mg, and 60mg sizes, with multiple active batches labeled “now shipping” as of April 2026.

One note on their internal review process. On February 6, 2026, Skye removed two misattributed test samples (IDs 4t7h769 and 9872swd) from their public database pending investigation. A vendor that pulls questionable data voluntarily is the inverse of the usual failure mode.

What to watch. The point score is lower than Polaris and Atomik. If your decision framework weighs raw score above documentation completeness, Polaris is the pick. If you weight the ability to verify every field, Skye is alone on the board.

Best for: researchers who want every COA field visible before they spend a dollar.

3. Atomik Labz: Tightest Quantity Accuracy on the Board

Atomik Labz has the tightest quantity accuracy of any tested vendor in our database: divergence range of -4.6% to +1.4% across four batches. This is the metric that fails industry-wide at a 12% rate, and Atomik owns it.

Grade A tentative, average score 8.4, 4 samples. The “tentative” label is a sample-size flag, not a quality flag. Purity is consistent at 99.60% to 99.73% across all four tests. Score range is 8.3 to 8.6, a window so narrow it either signals a genuinely locked-down process or a single good week at the fill line.

For dose-response research, label accuracy is load-bearing. A protocol that assumes 10mg in the vial and gets 7mg produces data that is wrong in a way HPLC purity cannot catch. Atomik's -4.6% to +1.4% band means labeled dose and actual dose are effectively the same number. That is rare on this list and rarer in the industry.

What to watch. All four tests come from a single batch, MM507, in 5mg vials only, and the test dates are May 6 and May 7, 2025. That is five months of data from one production run, not a year of independent lots. The tight score band is real. It is also the tight band you would expect when every sample comes from the same pour. Researchers building long protocols should plan to re-verify each new lot rather than assume the pattern carries, and should treat Atomik as a strong single-batch vendor until a second independent batch lands.

The cross-vendor context is useful here. Industry-wide, 12% of tirzepatide samples fail the >20% divergence threshold. Atomik's worst test came in at -4.6%, which is roughly a quarter of the failure line. Nexaph's worst came in at +43%. Same compound, same nominal research use, order-of-magnitude difference in what actually ships.

Best for: researchers whose protocol integrity depends on labeled dose matching actual dose, and who will re-test every new lot.

4. Simple Peptides: Grade B With One Catastrophic Outlier

Simple Peptides averages 8.4 across 6 tested batches with strong purity throughout, and one batch tested at +95% overfill, nearly double the labeled dose. Batch TIR3005212025-15, labeled 30mg, measured at 58.5mg actual.

A +95% overfill is not a rounding error or a QC variance. It is a manufacturing failure. In a research protocol, a single vial that contains double the labeled dose invalidates the entire data set that touches it. This is the cleanest possible illustration of the intro thesis: purity can pass while quantity fails catastrophically.

Without that one batch, Simple Peptides would grade A. The other samples score between 9.0 and 10.0. But outlier-removal is not how real-world buyers source. You do not get to pick which lot arrives at your door. You get what ships.

Grade B reflects the outlier's weight on a 6-sample history. Simple Peptides may still be viable for researchers who have lot-level COA verification built into their workflow and who will refuse any lot that does not match spec. Without that workflow, the variance risk is too high for anything load-bearing.

Purity data across the six samples sits between 98.9% and 99.7% HPLC, which is the cruel part of the story. The chemistry is correct. The fill step is not. A lab that can synthesize clean tirzepatide to pharma-grade purity and then deliver 58.5mg in a 30mg vial has a process-control problem, not a chemistry problem. Process problems are fixable, and they are also invisible to any buyer who stops reading at the HPLC line. The +95% lot is on the public record, which is how it landed on this page at all. Future lots will not carry the same label.

Skip if: you cannot verify each individual lot before use.

5. Peptide Crafters: Grade C, Improving Trend

Peptide Crafters averages Grade C at 6.3 across 6 batches, and the March 2026 batch tested at 8.5, the highest in the vendor's history. The trend is real. The history still drags.

Early batches showed +21.7% to +27.5% quantity overages, which is consistent with the industry-wide 12% failure pattern that motivates this whole list. Batch PC-J-T15 is the most recent sample inside the acceptable band. One clean lot is not enough to distinguish real process improvement from a single good production run.

Contrast this with Simple Peptides. Simple has a strong average dragged down by one outlier. Peptide Crafters has a weak average being pulled up by recent improvement. Both are mid-tier grade situations, and they look different from the inside.

Our position. We re-rate after the next two independent batch tests. Until then, Grade C stands, and researchers buying in the meantime are betting on trajectory, not established consistency. Pricing sits below the Grade A tier, which is why the question is open at all.

Purity has held steady across the 6-sample history at 99.1% or better. That is not the failure point. The +21.7% to +27.5% overages on early batches are the failure point, and they sit squarely inside the industry-wide quantity-accuracy problem. Six samples is also a thin history to declare a trend reversal from, especially when the improvement shows up on the most recent single lot.

Consider if: you accept trajectory risk in exchange for lower pricing and are willing to re-test yourself on arrival.

6. Nexaph: Grade E, Avoid

Nexaph has 47 independently tested tirzepatide samples, the largest sample set of any vendor in our database, with 99%+ purity on most samples and a Grade E on quantity accuracy. Forty-seven samples is a confirmed pattern, not a small-sample-size story.

One 60mg vial tested at 86mg, a +43.3% overfill. Individual batch scores range from 3.0 to 10.0. The distribution is not a distribution around a target. It is noise. You cannot predict what arrives when you order from Nexaph, and that unpredictability has held across a sample set most vendors will never reach.

Grade E is the lowest rating on our scale, and it is reserved for confirmed patterns of failure, not incidents. Nexaph appears able to synthesize pure tirzepatide. They cannot reliably fill a vial to the labeled amount. Those are two different problems, and the second one is the one that invalidates research.

This is exactly why Peptide Grades weights quantity accuracy as heavily as purity. A vendor who advertises 99% pure and delivers +43% over label is not a quality vendor. They are a lottery.

The failure mode is not confined to large vials. Individual batch scores span the full 3.0 to 10.0 range, meaning one order can arrive on spec and the next can be 40% off in either direction. There is no predictive signal inside the 47-sample set that tells a buyer which lot they are about to receive. That is what distinguishes a Grade E from a Grade C trend. Grade C vendors have a direction. Nexaph has a scatter plot.

Avoid. The purity numbers are real. The dose is not.

7. How to Use This List: Cross-Check Before You Buy

Vendor grades above reflect aggregate historical batch data. The vial you receive is a specific lot, not an average. Aggregate grades are a filter, not a guarantee. Polaris has 15 clean batches on record. The 16th could be the first outlier.

Practical checklist for any vendor on this list or in the full registry:

1. Request the COA for the exact lot printed on your vial, not a sample COA from the product page. A COA that cannot be tied to that batch number is marketing, not verification.
2. Verify HPLC purity above 99% and confirm the analytical method is labeled. A purity number with no method attached is a claim.
3. If the vendor publishes endotoxin data, confirm the result is below 0.5 EU/mg. Endotoxin above 0.5 EU/mg is a documented confound in immunological assays and may invalidate that subset of work while leaving other research usable.
4. Cross-reference reported weight against labeled weight. This is where 12% of samples fail industry-wide, and it is the step most buyers skip. An honest vendor overfilling by +18%, as Aavant Research did on a recent batch, turns a nominal 10mg/mL reconstitution into 11.8mg/mL. Every dose drawn is 18% stronger than the protocol assumes.
5. If any step above cannot be completed, the vendor grade does not apply to your purchase. Refuse the lot or re-plan the protocol around measured values.

The checklist runs about ten minutes per lot. Our COA reading guide walks through each field. For cross-compound grading, see our best peptide company comparison. A vendor grade is a starting point. The lot COA is the decision.

FAQ

Is it legal to buy tirzepatide for research?

Research-use-only peptides sit in a legal grey zone under current FDA enforcement. Vendors label product for research use, not human administration, and sell under that framing. The SAFE Drugs Act proposed in 2026 could close the loophole entirely. As of April 2026 the compounds are still being sold, but the regulatory trajectory is tightening. Never for human use. See our tirzepatide overview for the current regulatory posture.

Why did Peptide Sciences and Amino Asylum shut down?

Peptide Sciences stopped shipping on March 6, 2026, after sustained regulatory pressure following the ITC General Exclusion Order in January 2025. The operation had been running at roughly $7.4M per month. Amino Asylum was raided in June 2025, and its founders pleaded guilty in December 2025. The FDA removing tirzepatide from the shortage list on December 19, 2024 eliminated the compounding protection that both operations had relied on.

What is the difference between purity and quantity accuracy?

Purity is the percentage of compound in the vial that is tirzepatide, measured by HPLC. Quantity accuracy is whether the vial contains the labeled mg amount, measured by weight. A 99% pure vial can still be 30% off label. Twelve percent of tirzepatide samples tested industry-wide diverge by more than 20% from labeled dose.

Worked example. Nuscience Peptides posted 99.95% HPLC purity on a 10mg tirzepatide vial. The vial actually contained 6.53mg, a -34.7% quantity miss. A researcher following standard protocol would reconstitute that “10mg” vial with 2mL of bacteriostatic water expecting a 5mg/mL solution. The real concentration in the vial is 3.27mg/mL. Every dose drawn is 34.7% weaker than the protocol assumes, and the HPLC certificate the vendor published is still accurate. Purity passes while quantity fails. That is the spine of why we grade both.

How do I reconstitute research tirzepatide?

The standard ratio is 30mg vial plus 3mL bacteriostatic water for a 10mg/mL working solution. Scale proportionally for other vial sizes: 10mg plus 1mL also yields 10mg/mL, 5mg plus 0.5mL yields 10mg/mL.

Technique matters as much as ratio. Add bacteriostatic water slowly down the inside glass wall of the vial. Never splash directly onto the powder, which can denature the peptide at the contact point. Swirl gently to mix. Never shake, which introduces air bubbles and mechanical stress that degrades peptide chains. The solution should clear in one to three minutes. Discard the vial if it remains cloudy after ten minutes or shows any visible particulates.

Label every reconstituted vial with concentration, mix date, and 28-day discard date. Refrigerate between 36 and 46 degrees Fahrenheit. Never freeze a reconstituted solution. Ice crystal formation shears the peptide and produces an invisible potency loss that will not show on visual inspection.

Skye Peptides is the only vendor in our database publishing sterility data alongside the compound. All other vendors require independent sterility validation if that field matters to the research. This is not medical advice and the compounds are research-use only.

Which vendor is cheapest per mg?

Peptide Crafters and Simple Peptides are priced below the Grade A tier, and both carry grading concerns documented above. Polaris Peptides at $45 per 5mg is the cheapest Grade A option on the list. “Cheapest per mg” and “cheapest that meets your QC threshold” are not the same question, and most buyers are asking the wrong one.

How often is this list updated?

We re-rate when new independent batch data comes in. Atomik Labz is tentative pending more samples across additional batches. Peptide Crafters is under re-rate review based on the March 2026 batch. The vendor registry carries the most current grades and flags any rating under review.

Can I trust a vendor's own COA?

A vendor-published COA is a transparency signal, not independent verification. The vendor paid the lab and has an interest in the result. The strongest vendors publish third-party COAs matched to specific lot numbers that are verifiable against the lab's own records, which is what Skye does through Janoshik. Our COA verification methodology walks through how to tell a verifiable COA from a document that just looks like one.